Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A TCR-based Chimeric Antigen Receptor.
Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S. Walseng E, et al. Among authors: gaudernack g. Sci Rep. 2017 Sep 6;7(1):10713. doi: 10.1038/s41598-017-11126-y. Sci Rep. 2017. PMID: 28878363 Free PMC article.
NK cells specifically TCR-dressed to kill cancer cells.
Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S. Mensali N, et al. Among authors: gaudernack g. EBioMedicine. 2019 Feb;40:106-117. doi: 10.1016/j.ebiom.2019.01.031. Epub 2019 Jan 18. EBioMedicine. 2019. PMID: 30665853 Free PMC article.
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM. Dillard P, et al. Among authors: gaudernack g. Mol Ther. 2021 Mar 3;29(3):1199-1213. doi: 10.1016/j.ymthe.2020.11.019. Epub 2020 Nov 17. Mol Ther. 2021. PMID: 33212301 Free PMC article.
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM. Ellingsen EB, et al. Among authors: gaudernack g. J Immunother Cancer. 2022 May;10(5):e004345. doi: 10.1136/jitc-2021-004345. J Immunother Cancer. 2022. PMID: 35613827 Free PMC article.
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, Gaudernack G. Brunsvig PF, et al. Among authors: gaudernack g. Cancer Immunol Immunother. 2006 Dec;55(12):1553-64. doi: 10.1007/s00262-006-0145-7. Epub 2006 Feb 21. Cancer Immunol Immunother. 2006. PMID: 16491401 Free PMC article. Clinical Trial.
Transiently redirected T cells for adoptive transfer.
Almåsbak H, Rian E, Hoel HJ, Pulè M, Wälchli S, Kvalheim G, Gaudernack G, Rasmussen AM. Almåsbak H, et al. Among authors: gaudernack g. Cytotherapy. 2011 May;13(5):629-40. doi: 10.3109/14653249.2010.542461. Epub 2010 Dec 21. Cytotherapy. 2011. PMID: 21174490
217 results